## Management of Suspected Active Pediatric TB ### Clinical Diagnosis Framework **Key Point:** In children, TB diagnosis is **clinical and radiological**, not microbiological. Unlike adults, children with TB are often **sputum smear-negative** and **culture-negative** because they have paucibacillary disease (low bacterial load). ### Diagnostic Criteria for Pediatric TB (WHO/NTEP) A child is diagnosed with TB if they have: | Criterion | Status in This Case | |-----------|--------------------| | **Recent TB contact** | ✓ Father with smear-positive TB (3 months ago) | | **Clinical symptoms** | ✓ Cough, fever, anorexia (2 months) | | **TST positive** | ✓ 14 mm induration | | **Radiological findings** | ✓ Right upper lobe opacity with infiltrate | | **Microbiological confirmation** | ✗ Sputum/gastric aspirate negative | **High-Yield:** In pediatric TB, **absence of microbiological confirmation does NOT exclude TB diagnosis**. The combination of contact history + symptoms + TST positivity + CXR changes = **confirmed TB** and warrants treatment initiation. ### Why Microbiological Negativity Is Expected 1. **Paucibacillary disease:** Children have lower bacillary load than adults 2. **Limited airway involvement:** Primary TB is lymph node-dominant 3. **Difficulty in specimen collection:** Children cannot produce sputum easily 4. **Gastric aspirate limitations:** Sensitivity ~40–60% in pediatric TB **Clinical Pearl:** Waiting for culture results (which take 2–8 weeks) while withholding treatment exposes the child to disease progression and complications like tuberculous meningitis. ### Standard Anti-TB Regimen for Children **Mnemonic — HRZE × 2, HR × 4:** - **H**isoniazid - **R**ifampicin - **Z**inamide - **E**thambutol **Dosing in children (weight-based):** | Drug | Dose (mg/kg) | Formulation | |------|-------------|-------------| | **Isoniazid** | 10–15 | FDC (fixed-dose combination) | | **Rifampicin** | 15–20 | FDC | | **Pyrazinamide** | 25–35 | FDC | | **Ethambutol** | 15–25 | FDC | **Duration:** 2 months intensive (HRZE) + 4 months continuation (HR) = 6 months total [cite:Park 26e Ch 6] ### Why Other Options Are Incorrect **Option A (CT chest for malignancy):** - Unnecessary in a child with clear TB contact, positive TST, and typical CXR findings - Exposes child to radiation - Delays TB treatment **Option C (Repeat gastric aspirate):** - Delays treatment initiation - Repeated procedures are uncomfortable for the child - Negative results do not rule out TB in pediatric cases **Option D (Observe and repeat CXR):** - **Warning:** This is a common trap. Observation without treatment risks: - Disease progression to miliary TB - Tuberculous meningitis (highest risk in first 6 months) - Endobronchial TB with airway obstruction - Disseminated TB in immunocompromised children **High-Yield:** Delaying treatment in a symptomatic child with TB contact, positive TST, and CXR findings is **contraindicated**. ### Diagnostic Certainty in Pediatric TB **Key Point:** The **WHO and NTEP classify this child as having "confirmed TB"** based on: - Close contact with smear-positive case - Clinical symptoms consistent with TB - TST ≥5 mm (in contact) or ≥10 mm (in non-contact) - Radiological evidence of TB Microbiological confirmation is **not required** to initiate treatment. ### Treatment Monitoring After starting therapy: 1. **Clinical response:** Fever resolves, appetite improves (1–2 weeks) 2. **Radiological response:** CXR improvement by 2–3 months 3. **Adverse effects:** Monitor for hepatotoxicity, peripheral neuropathy (isoniazid) 4. **Adherence:** Directly observed therapy (DOT) is standard 5. **Nutritional support:** Essential for recovery
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.